Licensing status

Publication and contact information


Brain cancer

MicroRNA-17-92 (miR-17-92)

Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In a mouse model of medulloblastoma, miRNAs from the miR-17-92 cluster were overexpressed in medulloblastoma cells but not in normal cerebellum cells. In a mouse xenograft model of medulloblastoma, anti-miR-17 and anti-miR-19, which target miRNAs from the miR-17-92 cluster, decreased tumor proliferation and increased survival compared with saline. Next steps could include determining whether anti-miRNAs cross the blood brain barrier in patients with brain cancer or adopting new delivery strategies such as nanoparticles.

SciBX 6(48); doi:10.1038/scibx.2013.1376
Published online Dec. 19, 2013

Patent and licensing status unavailable

Murphy, B.L. et al. Cancer Res.;
published online Oct. 21, 2013;
Contact: Martine F. Roussel, St. Jude Children's Research Hospital, Memphis, Tenn.